Two Avalo Therapeutics directors to not stand for re-election at 2026 Annual Meeting

Avalo Therapeutics, Inc.

Dr. Jonathan Goldman and Mitchell Chan will not stand for re-election to the Board at the 2026 Annual Meeting.
They will continue to serve as board members until the 2026 Annual Meeting.
Decisions are not due to any disagreement with the Company regarding operations, policies, or practices.
The Board expressed gratitude for their service and contributions.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.